Have a personal or library account? Click to login
The effect of curcumin on symptoms and quality of life in patients with irritable bowel syndrome Cover

The effect of curcumin on symptoms and quality of life in patients with irritable bowel syndrome

Postępy Higieny i Medycyny Doświadczalnej
Volume 76 (2022): Issue 1 (January 2022)
By: Małgorzata Woźniak,  Adam Fabisiak,  Renata Talar-Wojnarowska and  Ewa Małecka-Wojciesko  
Open Access
|Aug 2022

Figures & Tables

Fig. 1

Disease activity scores on the IBS-SSS scale at initiation of treatment (visit 0) and after 4 (visit 1) and 12 weeks (visit 2) of curcumin treatment (mean ± SD), * p < 0.05 compared to visit 0, ** p < 0.01 compared to visit 1
Disease activity scores on the IBS-SSS scale at initiation of treatment (visit 0) and after 4 (visit 1) and 12 weeks (visit 2) of curcumin treatment (mean ± SD), * p < 0.05 compared to visit 0, ** p < 0.01 compared to visit 1

Fig. 2

Changes in individual categories of IBS-SSS from the start of treatment (visit 0), after 4 (visit 1), and 12 weeks (visit 2) of curcumin consumption * p < 0.05, compared to visit 0, ** p < 0,01, compared to visit 0
Changes in individual categories of IBS-SSS from the start of treatment (visit 0), after 4 (visit 1), and 12 weeks (visit 2) of curcumin consumption * p < 0.05, compared to visit 0, ** p < 0,01, compared to visit 0

Fig. 3

Results of overall quality of life scale (IBS-QoL) at initiation of treatment (visit 0) and after 4 (visit 1) and 12 weeks (visit 2) of curcumin consumption (mean ± SD). * p < 0.05 compared to visit 0, ** p < 0.01 compared to visit 1
Results of overall quality of life scale (IBS-QoL) at initiation of treatment (visit 0) and after 4 (visit 1) and 12 weeks (visit 2) of curcumin consumption (mean ± SD). * p < 0.05 compared to visit 0, ** p < 0.01 compared to visit 1

Fig. 4

Quality of life results in individual domains at the start of treatment (visit 0), after 4 (visit 1), and after 12 weeks (visit 2) of curcumin use. * p < 0.05, compared to visit 0, ** p < 0.05, compared to visit 0
Quality of life results in individual domains at the start of treatment (visit 0), after 4 (visit 1), and after 12 weeks (visit 2) of curcumin use. * p < 0.05, compared to visit 0, ** p < 0.05, compared to visit 0

Characteristics of the study group

nSex 51
female n (%)30 (58.8)p = 0.08
male n (%)21 (41.2)
Age (years) 52.6 ± 15.9
female56.9 ± 14.2p = 0.02
male46.6 ± 16.5
Severity of IBSn (%)mild4 (7.8)p = 0.55
moderate25 (49.0)
severe22 (43.2)
Type of IBSn (%)diarrhea35 (68.6)p < 0.05
constipation16 (31.4)
DOI: https://doi.org/10.2478/ahem-2022-0048 | Journal eISSN: 1732-2693
Journal RSS Feed
Language: English
Page range: 345 - 350
Submitted on: Jan 18, 2022
Accepted on: May 15, 2022
Published on: Aug 9, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
curcumin,
irritable bowel syndrome,
quality of life,
IBS treatment
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Medicine,
Basic medical science,
Immunology

© 2022 Małgorzata Woźniak, Adam Fabisiak, Renata Talar-Wojnarowska, Ewa Małecka-Wojciesko, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 76 (2022): Issue 1 (January 2022)Next article